ANRO vs. PCRX, BLTE, KNSA, SYRE, MNKD, ANIP, AKRO, DAWN, MIRM, and ABCL
Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Pacira BioSciences (PCRX), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), Spyre Therapeutics (SYRE), MannKind (MNKD), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Day One Biopharmaceuticals (DAWN), Mirum Pharmaceuticals (MIRM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation.
Pacira BioSciences presently has a consensus target price of $47.40, indicating a potential upside of 56.28%. Alto Neuroscience has a consensus target price of $32.33, indicating a potential upside of 170.35%. Given Pacira BioSciences' higher possible upside, analysts plainly believe Alto Neuroscience is more favorable than Pacira BioSciences.
99.7% of Pacira BioSciences shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Pacira BioSciences received 803 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 100.00% of users gave Alto Neuroscience an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
In the previous week, Pacira BioSciences had 7 more articles in the media than Alto Neuroscience. MarketBeat recorded 8 mentions for Pacira BioSciences and 1 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.03 beat Pacira BioSciences' score of 0.00 indicating that Pacira BioSciences is being referred to more favorably in the media.
Pacira BioSciences has a net margin of 10.34% compared to Pacira BioSciences' net margin of 0.00%. Alto Neuroscience's return on equity of 12.98% beat Pacira BioSciences' return on equity.
Pacira BioSciences has higher revenue and earnings than Alto Neuroscience.
Summary
Pacira BioSciences beats Alto Neuroscience on 11 of the 14 factors compared between the two stocks.
Get Alto Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alto Neuroscience Competitors List
Related Companies and Tools
